These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31305338)

  • 1. Pharmacokinetics of Single Doses of Methadone and Buprenorphine in Blood and Oral Fluid in Healthy Volunteers and Correlation With Effects on Psychomotor and Cognitive Functions.
    Strand MC; Ramaekers JG; Gjerde H; Mørland J; Vindenes V
    J Clin Psychopharmacol; 2019; 39(5):489-493. PubMed ID: 31305338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical trial on the acute effects of methadone and buprenorphine on actual driving and cognitive function of healthy volunteers.
    Strand MC; Vindenes V; Gjerde H; Mørland JG; Ramaekers JG
    Br J Clin Pharmacol; 2019 Feb; 85(2):442-453. PubMed ID: 30515857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
    Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
    Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180 mg alone and with alcohol, with hydroxyzine hydrochloride 50 mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car.
    Ridout F; Shamsi Z; Meadows R; Johnson S; Hindmarch I
    Clin Ther; 2003 May; 25(5):1518-38. PubMed ID: 12867226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial.
    Soyka M; Hock B; Kagerer S; Lehnert R; Limmer C; Kuefner H
    J Clin Psychopharmacol; 2005 Oct; 25(5):490-3. PubMed ID: 16160628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.
    Harris DS; Mendelson JE; Lin ET; Upton RA; Jones RT
    Clin Pharmacokinet; 2004; 43(5):329-40. PubMed ID: 15080765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of buprenorphine and methadone in methadone-maintained subjects.
    Walsh SL; June HL; Schuh KJ; Preston KL; Bigelow GE; Stitzer ML
    Psychopharmacology (Berl); 1995 Jun; 119(3):268-76. PubMed ID: 7675960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of three therapeutic doses of codeine/paracetamol on driving performance, a psychomotor vigilance test, and subjective feelings.
    Amato JN; Marie S; Lelong-Boulouard V; Paillet-Loilier M; Berthelon C; Coquerel A; Denise P; Bocca ML
    Psychopharmacology (Berl); 2013 Jul; 228(2):309-20. PubMed ID: 23474890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1995 Feb; 272(2):628-38. PubMed ID: 7853176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates.
    Rapeli P; Fabritius C; Kalska H; Alho H
    BMC Clin Pharmacol; 2011 Aug; 11():13. PubMed ID: 21854644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.
    Kuhlman JJ; Lalani S; Magluilo J; Levine B; Darwin WD
    J Anal Toxicol; 1996 Oct; 20(6):369-78. PubMed ID: 8889672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients.
    Lintzeris N; Mitchell TB; Bond AJ; Nestor L; Strang J
    Drug Alcohol Depend; 2007 Dec; 91(2-3):187-94. PubMed ID: 17624687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
    Rosado J; Walsh SL; Bigelow GE; Strain EC
    Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.
    Fihlman M; Hemmilä T; Hagelberg NM; Kuusniemi K; Backman JT; Laitila J; Laine K; Neuvonen PJ; Olkkola KT; Saari TI
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1363-1371. PubMed ID: 27510521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can patients receiving opioid maintenance therapy safely drive? A systematic review of epidemiological and experimental studies on driving ability with a focus on concomitant methadone or buprenorphine administration.
    Strand MC; Fjeld B; Arnestad M; Mørland J
    Traffic Inj Prev; 2013; 14(1):26-38. PubMed ID: 23259516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute administration of buprenorphine in humans: partial agonist and blockade effects.
    Walsh SL; Preston KL; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1995 Jul; 274(1):361-72. PubMed ID: 7542336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers.
    Jensen ML; Sjøgren P; Upton RN; Foster DJ; Bonde P; Graae C; Skram U; Stevner L; Christrup LL
    Basic Clin Pharmacol Toxicol; 2008 Jul; 103(1):94-101. PubMed ID: 18598301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Less driving impairment on buprenorphine than methadone in drug-dependent patients?
    Soyka M; Horak M; Dittert S; Kagerer S
    J Neuropsychiatry Clin Neurosci; 2001; 13(4):527-8. PubMed ID: 11748323
    [No Abstract]   [Full Text] [Related]  

  • 19. Opioid plasma concentrations in methadone-and buprenorphine-maintained patients.
    Jagsch R; Gombas W; Schindler SD; Eder H; Moody DE; Fischer G
    Addict Biol; 2005 Dec; 10(4):365-71. PubMed ID: 16318959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients.
    Lintzeris N; Mitchell TB; Bond A; Nestor L; Strang J
    J Clin Psychopharmacol; 2006 Jun; 26(3):274-83. PubMed ID: 16702892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.